While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

Servier isn’t the first drug developer to spot a silver lining in Google Cloud. Ginkgo inked its own five-year partnership in ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...